PRENasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as PRENW

Prenetics Global Ltd

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026

$19.02+0.50 (+2.70%)

Close on Oct 19, 2026

Market cap: –
P/E (TTM): –
Dividend yield: –

Prenetics Global Ltd cash flow statement

AnnualQuarterlyTTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Stock-Based Compensation	7.61	7.85	11	32	22	1.62
Change in Accounts Receivable	-0.53	-0.56	38	6.97	-24	-20
Change in Inventory	-2.79	1.32	-1.73	1.26	-2.33	-3.75
Change in Accounts Payable	0.33	-4.68	-5.62	-2.63	-3.46	9.71
Operating Cash Flow	-22	-29	-14	15	13	-2.88
Capital Expenditures	-0.21	-1.01	-0.35	-4.95	-8.55	-2.86
Acquisitions	0	-8.35	0	-3.42	0	-2.93
Sale of Property, Plant & Equipment	0.01	0.04	0.10	0.05	0.71	0.01
Investing Cash Flow	-36	39	-83	-46	-22	-5.97
Financing Cash Flow	37	-3.34	-4.70	143	29	12
Foreign Exchange Rate Adjustments	-0.07	0.22	0.47	-0.32	0.09	-0.02
Free Cash Flow	-22	-30	-14	9.57	4.87	-5.74

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Dec 31, 2025

Profitability, FY2025

Gross margin: 52.8%
Operating margin: -48.1%
Net margin: -40.8%
Return on equity, FY2025: -23.1%

Financial strength

Current ratio: 2.97
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 111.9%

Valuation

P/E ratio: –
Price to sales: –
Price to book: –
Dividend yield: –